



Drug delivery nanosystems for intracellular release of doxorubicin improve the clonogenic inactivation of X-Rays in human cervical adenocarcinoma cells



Roxana Cristina Popescu^{1,2}, Verena Kopatz³, Hiltraud Hosser⁴, Frank Schneider⁴, Ecaterina Andronescu², Frederik Wenz⁵, Frank Giordano⁴, Carsten Herskind⁴, Wolfgang Doerr^{3*}, Marlon R. Veldwijk⁴, Diana Savu¹


¹ Department of Life and Environmental Physics, "Horia Hulubei" National Institute for Research and Development in Physics and Nuclear Engineering, Magurele, Romania; ² Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, Bucharest, Romania; ³ Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria; ⁴ Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; ⁵ University Medical Center Freiburg, Freiburg, Germany; (* deceased)

roxana.popescu@nipne.ro




Objectives: Radiosensitization using nanoparticles is a promising approach for the improvement of radiotherapy cytotoxic effects against chemo-/radio-resistant tumor cells and simultaneous reduction of adverse effects in surrounding healthy tissues. Here, we propose a method based on iron oxide nanoparticles (IONP) for the intracellular delivery of the anthracycline doxorubicin to enhance the cytotoxic effects of X-Rays.

Materials and methods: We synthesized and characterized iron oxide nanoparticles functionalized with polyethylene glycol (IONP_{CO}) in order to be used as drug delivery systems for doxorubicin (IONP_{DOX}). The biological effects were assessed in 2D and 3D cell cultures of human cervical adenocarcinoma cells (HeLa). Uptake and retention of IONP were evaluated using optical, fluorescence and transmission electron microscopy. Clonogenic survival was used to measure the radiosensitization effect of IONP at different doses of low (50 kV), medium (150 kV) and high (6 MV) X-Rays in both 2D and 3D cell models. Data are presented as mean ± SEM (n=3).




Structural and compositional characterization of IONP [Popescu et al. Sci Rep. 10: 10530 (2020)].




Delivery of doxorubicin from IONP_{DOX} [Popescu et al. Sci Rep. 10: 10530 (2020)].





Efficient internalization of IONP_{CO} and IONP_{DOX} in HeLa cells occurred through pino- and endocytosis, with both IONP accumulating in the perinuclear area [Popescu et al. Sci Rep. 10: 10530 (2020)].



In 2D cell cultures, IONP_{CO} enhanced the radiosensitivity (dose-modifying factor, DMF) of 50 kV X-Rays with a DMF_{SF0.1} = 1.13 ± 0.06 (P<0.05), but did not determine any radiosensitizing effect after 6MV irradiation. IONP_{DOX} enhanced the clonogenic inactivation of 6 MV X-rays in 2D HeLa cell cultures with a DMF_{SF0.1} = 1.3 ± 0.1 (P<0.05) and DMF_{SF0.1} = 1.29 ± 0.02 in case of 150 kV (P<0.05).



Efficient penetration of the IONP_{DOX} was obtained after 48h of exposure in 3D spheroids and exposure to 150 kV led to a DMF_{SF0.1} = 1.07 ± 0.07 (NS).



Conclusions: The radiosensitization effect was dependent on the radiation energy for drug-free nanoparticles, IONP_{CO} showing a significant clonogenic inactivation compared to irradiation alone, in case of low energy X-Rays exposure, while IONP_{DOX} determined radiomodulatory effects for both medium and high energy X-Rays. The IONP are good candidates for the controlled delivery of DOX to enhance the cytotoxic effects of ionizing radiation.

Acknowledgement: This work was supported by the Deutscher Akademischer Austauschdienst (DAAD) grant No. 57299291, by Bundesministerium für Bildung, Wissenschaft und Forschung (BMBWF) through Austrian Agency for International Cooperation in Education and Research (OeAD) grant No. ICM-2018-10056, by Romanian Ministry of Education and Research grants no. PN18090202/2018, PN19060203/2019, 5PCCDI/2018 and 64PCCDI/2018 and the Operational Programme Human Capital of the Ministry of European Funds through the Financial Agreement 51668/09.07.2019, SMIS code 124705.